The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, reflecting a robust CAGR of 26.2%.

HIV franchise remains its biggest value driver. The firm believes a strong launch of lenacapavir in pre-exposure ...

"Stigma isn't just a social issue; it's a public health crisis." says Marcus Wilson, Gilead Senior Director, U.S. Public Affairs, HIV Advocacy. "It determines the quality of care that people ...

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is heading for a takeover by Gilead Sciences in a $405 million deal.

Gilead Sciences has bolstered its position ... which includes options and licenses to cell engineering and manufacturing technologies invented and developed in the university's laboratories.

Additionally, manufacturers offer patient assistance programs, such as Kite Konnect by Gilead, which help with reimbursement support, logistics, and treatment navigation. With continuous research ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Transgender people receiving gender-affirming hormone therapy have a 37% lower chance of acquiring HIV, and for people living with HIV, hormone therapy appears to offer a 44% lower chance of the ...